Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
about
Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacyDelafloxacin: design, development and potential place in therapyA randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycinIn Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.New quinolone antibiotics: a survey of the literature from 2005 to 2010.Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes.New treatment options for lower respiratory tract infections.In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization.
P2860
Q26824268-3363C29B-E643-4E67-A807-EB8576EFA145Q34554381-0F973271-5E50-444D-90C1-44E51D08588EQ36551335-C08A6BA3-23F7-4DFF-8841-EAFC522DC9F5Q37120092-91690A14-9A06-4AB2-8F73-E2B63F203990Q37774376-D2ECFA40-BCA2-494C-A000-45ED355819F3Q37861190-BDFBEB2A-9661-4ADA-9491-093712300D33Q40111519-CF4DA3E9-CD4E-43DD-BA2A-F2D4E4F01F47Q40342746-3BAE5F10-B6CF-468B-ACFD-42A363084A64Q41005606-89984540-9B9F-499C-97A7-BAED9243AC6AQ41194442-7AAF2251-E3BB-4654-A9D8-2BAEE5F8E78FQ50065370-CB227119-FACE-4EFF-9CA4-78743AFA6048Q52579373-CB453AA3-0CC2-4C7B-9D6F-ED7000E1DA08Q54297668-330B6E49-62F0-4E01-85A4-99E2F291E9CB
P2860
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
@en
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
@nl
type
label
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
@en
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
@nl
prefLabel
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
@en
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
@nl
P2093
P356
P1476
Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492.
@en
P2093
P304
P356
10.1093/JAC/DKH180
P407
P577
2004-03-31T00:00:00Z